Physician profile
Lucy M Lomas
NPI 1184854432
$1,748.74
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $288 · 2021: $715 · 2022: $430.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $333.69 | 2019-2022 | |
| Agile Therapeutics, INC. | $186.23 | 2021-2022 | |
| Abbvie INC. | $171.53 | 2019-2022 | |
| Exeltis, USA INC. | $169.89 | 2020-2022 | |
| Mylan Pharmaceuticals INC. | $148.24 | 2019-2022 | |
| Evofem Biosciences, INC. | $123.65 | 2021-2022 | |
| Hologic Sales and Service, LLC | $83.88 | 2019-2022 | |
| Pfizer INC. | $67.69 | 2019-2021 | |
| Lupin INC. | $67.36 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $67.29 | 2021 | |
| Scynexis, INC. | $50.30 | 2022 | |
| Organon LLC | $45.90 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.15 | 2019-2020 | |
| Medicem INC. | $44.44 | 2020-2021 | |
| Sage Therapeutics, LLC | $39.03 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $35.18 | 2020 | |
| Boston Scientific Corporation | $32.45 | 2019-2020 | |
| Minerva Surgical, INC | $21.89 | 2021 | |
| Merck Sharp & Dohme LLC | $14.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Lomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.